Treatment of carcinoid of the lung
PURPOSE OF REVIEWPulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors. During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors....
Gespeichert in:
| Veröffentlicht in: | Current opinion in oncology 2004-03, Vol.16 (2), p.146-149 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 2 |
| container_start_page | 146 |
| container_title | Current opinion in oncology |
| container_volume | 16 |
| creator | Kosmidis, Paris A |
| description | PURPOSE OF REVIEWPulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors. During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors.
RECENT FINDINGSHistologic subclassification of carcinoid tumors into atypical and typical is of paramount importance. Genetic changes in these subclasses are now well-known and are helpful for the differentiation. The biologic behavior of typical and atypical carcinoids is completely different, and treatment planning is based on this information. Surgery is the treatment of choice for localized carcinoid tumors and includes lymphadenectomy. In metastatic disease, chemotherapy with a cisplatin-based or streptozotocin-based combination is moderately effective. Palliation with biotherapy including interferon, somatostatin analogs, and octreotide is encouraging. Liver embolization is an option for symptomatic liver involvement.
SUMMARYPulmonary carcinoids are rare tumors, and our understanding of their histopathology and biologic behavior are the most important factors for treatment planning. Surgery is the treatment of choice for cure. |
| doi_str_mv | 10.1097/00001622-200403000-00011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71815994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71815994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3561-e051b0c3d31d25e80487ef54906476a7431479aea29cbd1b230957c06d842be73</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqXwCyhiwS4wfsXxElW8pEpsisTOcpwJDeRR7EQVf49LC6yYjWfsc8fSISShcEVBq2uIRTPGUgYggMcp3d7QAzKlktNUAX85jH18THMlsgk5CeEtEkyDPiYTKkFJDWpKLpYe7dBiNyR9lTjrXd31dbkdhhUmzdi9npKjyjYBz_bnjDzf3S7nD-ni6f5xfrNIHZcZTREkLcDxktOSScxB5AorKTRkQmVWCU6F0hYt064oacE4aKkcZGUuWIGKz8jlbu_a9x8jhsG0dXDYNLbDfgxG0ZxKrUUE8x3ofB-Cx8qsfd1a_2komK0f8-PH_Pox335i9Hz_x1i0WP4F90IiIHbApm8G9OG9GTfozQptM6zMf975F2rrbLo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71815994</pqid></control><display><type>article</type><title>Treatment of carcinoid of the lung</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Kosmidis, Paris A</creator><creatorcontrib>Kosmidis, Paris A</creatorcontrib><description>PURPOSE OF REVIEWPulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors. During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors.
RECENT FINDINGSHistologic subclassification of carcinoid tumors into atypical and typical is of paramount importance. Genetic changes in these subclasses are now well-known and are helpful for the differentiation. The biologic behavior of typical and atypical carcinoids is completely different, and treatment planning is based on this information. Surgery is the treatment of choice for localized carcinoid tumors and includes lymphadenectomy. In metastatic disease, chemotherapy with a cisplatin-based or streptozotocin-based combination is moderately effective. Palliation with biotherapy including interferon, somatostatin analogs, and octreotide is encouraging. Liver embolization is an option for symptomatic liver involvement.
SUMMARYPulmonary carcinoids are rare tumors, and our understanding of their histopathology and biologic behavior are the most important factors for treatment planning. Surgery is the treatment of choice for cure.</description><identifier>ISSN: 1040-8746</identifier><identifier>EISSN: 1531-703X</identifier><identifier>DOI: 10.1097/00001622-200403000-00011</identifier><identifier>PMID: 15075907</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Antineoplastic Agents - therapeutic use ; Carcinoid Tumor - genetics ; Carcinoid Tumor - pathology ; Carcinoid Tumor - secondary ; Carcinoid Tumor - therapy ; Chemotherapy, Adjuvant - methods ; Humans ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Survival Rate</subject><ispartof>Current opinion in oncology, 2004-03, Vol.16 (2), p.146-149</ispartof><rights>2004 Lippincott Williams & Wilkins, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3561-e051b0c3d31d25e80487ef54906476a7431479aea29cbd1b230957c06d842be73</citedby><cites>FETCH-LOGICAL-c3561-e051b0c3d31d25e80487ef54906476a7431479aea29cbd1b230957c06d842be73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15075907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kosmidis, Paris A</creatorcontrib><title>Treatment of carcinoid of the lung</title><title>Current opinion in oncology</title><addtitle>Curr Opin Oncol</addtitle><description>PURPOSE OF REVIEWPulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors. During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors.
RECENT FINDINGSHistologic subclassification of carcinoid tumors into atypical and typical is of paramount importance. Genetic changes in these subclasses are now well-known and are helpful for the differentiation. The biologic behavior of typical and atypical carcinoids is completely different, and treatment planning is based on this information. Surgery is the treatment of choice for localized carcinoid tumors and includes lymphadenectomy. In metastatic disease, chemotherapy with a cisplatin-based or streptozotocin-based combination is moderately effective. Palliation with biotherapy including interferon, somatostatin analogs, and octreotide is encouraging. Liver embolization is an option for symptomatic liver involvement.
SUMMARYPulmonary carcinoids are rare tumors, and our understanding of their histopathology and biologic behavior are the most important factors for treatment planning. Surgery is the treatment of choice for cure.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoid Tumor - genetics</subject><subject>Carcinoid Tumor - pathology</subject><subject>Carcinoid Tumor - secondary</subject><subject>Carcinoid Tumor - therapy</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Humans</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Survival Rate</subject><issn>1040-8746</issn><issn>1531-703X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqXwCyhiwS4wfsXxElW8pEpsisTOcpwJDeRR7EQVf49LC6yYjWfsc8fSISShcEVBq2uIRTPGUgYggMcp3d7QAzKlktNUAX85jH18THMlsgk5CeEtEkyDPiYTKkFJDWpKLpYe7dBiNyR9lTjrXd31dbkdhhUmzdi9npKjyjYBz_bnjDzf3S7nD-ni6f5xfrNIHZcZTREkLcDxktOSScxB5AorKTRkQmVWCU6F0hYt064oacE4aKkcZGUuWIGKz8jlbu_a9x8jhsG0dXDYNLbDfgxG0ZxKrUUE8x3ofB-Cx8qsfd1a_2komK0f8-PH_Pox335i9Hz_x1i0WP4F90IiIHbApm8G9OG9GTfozQptM6zMf975F2rrbLo</recordid><startdate>200403</startdate><enddate>200403</enddate><creator>Kosmidis, Paris A</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200403</creationdate><title>Treatment of carcinoid of the lung</title><author>Kosmidis, Paris A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3561-e051b0c3d31d25e80487ef54906476a7431479aea29cbd1b230957c06d842be73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoid Tumor - genetics</topic><topic>Carcinoid Tumor - pathology</topic><topic>Carcinoid Tumor - secondary</topic><topic>Carcinoid Tumor - therapy</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Humans</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Survival Rate</topic><toplevel>online_resources</toplevel><creatorcontrib>Kosmidis, Paris A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kosmidis, Paris A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of carcinoid of the lung</atitle><jtitle>Current opinion in oncology</jtitle><addtitle>Curr Opin Oncol</addtitle><date>2004-03</date><risdate>2004</risdate><volume>16</volume><issue>2</issue><spage>146</spage><epage>149</epage><pages>146-149</pages><issn>1040-8746</issn><eissn>1531-703X</eissn><abstract>PURPOSE OF REVIEWPulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors. During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors.
RECENT FINDINGSHistologic subclassification of carcinoid tumors into atypical and typical is of paramount importance. Genetic changes in these subclasses are now well-known and are helpful for the differentiation. The biologic behavior of typical and atypical carcinoids is completely different, and treatment planning is based on this information. Surgery is the treatment of choice for localized carcinoid tumors and includes lymphadenectomy. In metastatic disease, chemotherapy with a cisplatin-based or streptozotocin-based combination is moderately effective. Palliation with biotherapy including interferon, somatostatin analogs, and octreotide is encouraging. Liver embolization is an option for symptomatic liver involvement.
SUMMARYPulmonary carcinoids are rare tumors, and our understanding of their histopathology and biologic behavior are the most important factors for treatment planning. Surgery is the treatment of choice for cure.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>15075907</pmid><doi>10.1097/00001622-200403000-00011</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8746 |
| ispartof | Current opinion in oncology, 2004-03, Vol.16 (2), p.146-149 |
| issn | 1040-8746 1531-703X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71815994 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antineoplastic Agents - therapeutic use Carcinoid Tumor - genetics Carcinoid Tumor - pathology Carcinoid Tumor - secondary Carcinoid Tumor - therapy Chemotherapy, Adjuvant - methods Humans Lung Neoplasms - genetics Lung Neoplasms - pathology Lung Neoplasms - therapy Survival Rate |
| title | Treatment of carcinoid of the lung |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T18%3A10%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20carcinoid%20of%20the%20lung&rft.jtitle=Current%20opinion%20in%20oncology&rft.au=Kosmidis,%20Paris%20A&rft.date=2004-03&rft.volume=16&rft.issue=2&rft.spage=146&rft.epage=149&rft.pages=146-149&rft.issn=1040-8746&rft.eissn=1531-703X&rft_id=info:doi/10.1097/00001622-200403000-00011&rft_dat=%3Cproquest_cross%3E71815994%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71815994&rft_id=info:pmid/15075907&rfr_iscdi=true |